Drug Pipeline News

Latest News

ZY5301 tablet effective for chronic pelvic pain

July 25th 2024

These results indicated a significant reduction of CPP from 12 weeks of ZY5301 treatment. Investigators recommended a ZY5301 600 mg/d dose be investigated in a phase 3 trial.

FDA approves femlyv as the first orally disintegrating tablet for pregnancy prevention

By Celeste Krewson, Assistant Editor

July 24th 2024

First patient dosed in RECONNECT trial of RE104 for postpartum depression

By Celeste Krewson, Assistant Editor

July 23rd 2024

FDA grants fast track to 99mTc-maraciclatide for endometriosis diagnosis

By Celeste Krewson, Assistant Editor

July 2nd 2024

Contemporary OB/GYN week in review: mifepristone, cervical cancer, and more

By Celeste Krewson, Assistant Editor

June 14th 2024

Latest CME Events & Activities

Community Practice Connections™: 14th Annual International Symposium on Ovarian Cancer and Other Gynecologic Malignancies

4th Annual International Congress on the Future of Women’s Health™

Patient, Provider, and Caregiver Connection™: Exploring Unmet Needs In Postpartum Depression – Making the Case for Early Detection and Novel Treatments

Identifying Health Care Inequities in Screening, Diagnosis, and Trial Access for Breast Cancer Care: Taking Action With Evidence-Based Solutions

16th Annual International Symposium on Ovarian Cancer and Other Gynecologic Malignancies™

May 3, 2025

More News

Agile Therapeutics announces nationwide launch of Twirla transdermal system, a new contraceptive patch

Lindsey Carr, Editor

December 7th 2020

Agile Therapeutics, Inc. announced today the U.S. commercial launch of Twirla (levonorgestrel and ethinyl estradiol) transdermal system, a new non-daily, non-invasive contraceptive patch.

<1 2 3 4

Advertise

Job Board

Do Not Sell My Personal Information

Contact Info

2 Commerce Drive
Cranbury, NJ 08512

609-716-7777